NextPlat Q2 FY26 net loss narrows 92% to $144,000; revenue rises 21% sequentially to $11.9 million
NXPL•Management cites turnaround progress and Q3 launch plans
CEO David Phipps said the results mark an inflection point in the turnaround, driven by a shift toward higher-margin 340B contracted pharmacy services.
Management expects to launch a nationwide medication-fulfillment website in Q3 2026, aiming to expand PharmcoRx beyond Florida.
Quarterly results improve on higher-margin pharmacy revenue
NextPlat posted Q2 revenue of $11.9 million, up about 21% sequentially, with gross margin rising to about 40%.
Net loss attributable to common stockholders narrowed about 92% year over year to $144,000, or $0.05 per share.
Contracted pharmacy revenue more than doubled to about $2.2 million, while e-commerce revenue climbed about 27% sequentially to about $4.1 million.
